MedTrace Logo

Personalised Medicine in the Identification of Preclinical Cognitive Impairment. Development of a Predictive Risk Model

NCT06114290 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1150

Last updated 2024-01-11

No results posted yet for this study

Summary

The goal of this observational study is to use the combined power of the integration of clinical, molecular, proteomic, genomic, care, social, environmental and behavioural data in patients, using advanced artificial intelligence techniques for data processing and analysis, in order to generate predictive models for the preclinical detection of CI in the population aged 55-70 years.

Conditions

  • Cognitive Dysfunction

Sponsors & Collaborators

  • Instituto de Investigación Biomédica de Salamanca

    collaborator OTHER

  • Carlos III Health Institute

    collaborator OTHER_GOV

  • Universidad Complutense de Madrid

    collaborator OTHER

  • Biomedical Research Networking Centre on Frailty and Healthy Ageing

    collaborator UNKNOWN

  • Biomedical Research Networking Centre on Mental Health

    collaborator UNKNOWN

  • Institute of Biomedical Research of Lleida

    collaborator UNKNOWN

  • Institute of Health and Biomedical Research of Alicante

    collaborator UNKNOWN

  • Carlos III University of Madrid

    collaborator UNKNOWN

  • University of Vigo

    collaborator OTHER

  • Foundation for Biosanitary Research and Innovation in Primary Health Care

    collaborator UNKNOWN

  • Biomedical Research Networking Centre on Epidemiology and Public Health

    collaborator UNKNOWN

  • Research Network on Chronicity, Primary Care and Health Prevention and Promotion

    collaborator UNKNOWN

  • Instituto de Salud Carlos III

    lead OTHER_GOV

Principal Investigators

  • Angeles Almeida, PhD · Consejo Superior de Investigaciones Científicas (CSIC)

  • Rodrigo Barderas, PhD · Instituto de Salud Carlos III

  • MARIA TERESA MORENO-CASBAS, PhD · Nursing and Healthcare Research Unit (Investén-isciii). Instituto de Salud Carlos III. Madrid

Eligibility

Min Age
55 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2025-07-31
Completion
2025-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06114290 on ClinicalTrials.gov